Savient Pharmaceuticals has reported Phase III results for its compound Puricase (PEG-uricase).
Savient reported on anecdotal findings of gout tophus eradication after 12 weeks of PEG-uricase treatment. The response rate, defined as the proportion of patients that had a mean serum uric acid level below 6 mg/dL, was over 50 percent for all dose groups, with the 8 mg/2 week dose group showing over 80 percent response rate.